Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Gene ; 859: 147213, 2023 Apr 05.
Article in English | MEDLINE | ID: mdl-36690225

ABSTRACT

Primary familial brain calcifications (PFBC) is characterized by bilateral and symmetrical deposition of inorganic phosphate, mainly in the basal ganglia, thalamus, cerebellum, and dentate nucleus. The symptoms resemble other neuropsychiatric conditions, such as Parkinsonism, dementia, migraine, and mood disorders. Pathogenic variants in six genes have been associated with this disorder, four linked to the autosomal dominant mode (SLC20A2, PDGFRB, PDGFB, and XPR1) and two linked to the recessive fashion (MYORG and JAM2). Herein, we report a young 24-year-old patient with a medical history of bilateral and symmetrical brain calcification and neuropsychiatric symptoms that include movement disturbances (chorea and dystonia), chronic migraine, unexplained tinnitus, and mood swings. After whole-exome sequencing, she was diagnosed with a novel homozygous MYORG variant (c.912_914del; p.(Ser305del)). In silico analysis showed that the variant is located on the extracellular domain of MYORG protein and is predicted to be disease-causing (likely pathogenic), implying that protein features might be affected. This study describes the second Brazilian case of MYORG PFBC-causative gene. Furthermore, it highlights the early age and onset of symptoms of the proband, especially in regard to movement disorders.


Subject(s)
Brain Diseases , Calcinosis , Mental Disorders , Neurodegenerative Diseases , Female , Humans , Young Adult , Adult , Brain Diseases/genetics , Brain Diseases/metabolism , Brain Diseases/pathology , Family , Calcinosis/genetics , Neurodegenerative Diseases/genetics , Cerebellum/metabolism , Mutation , Sodium-Phosphate Cotransporter Proteins, Type III/genetics , Sodium-Phosphate Cotransporter Proteins, Type III/metabolism , Brain/metabolism , Pedigree
2.
Ann Neurol ; 91(5): 652-669, 2022 05.
Article in English | MEDLINE | ID: mdl-35226368

ABSTRACT

OBJECTIVE: Astrocytes play a significant role in the pathology of multiple sclerosis (MS). Nevertheless, for ethical reasons, most studies in these cells were performed using the Experimental Autoimmune Encephalomyelitis model. As there are significant differences between human and mouse cells, we aimed here to better characterize astrocytes from patients with MS (PwMS), focusing mainly on mitochondrial function and cell metabolism. METHODS: We obtained and characterized induced pluripotent stem cell (iPSC)-derived astrocytes from three PwMS and three unaffected controls, and performed electron microscopy, flow cytometry, cytokine and glutamate measurements, gene expression, in situ respiration, and metabolomics. We validated our findings using a single-nuclei RNA sequencing dataset. RESULTS: We detected several differences in MS astrocytes including: (i) enrichment of genes associated with neurodegeneration, (ii) increased mitochondrial fission, (iii) increased production of superoxide and MS-related proinflammatory chemokines, (iv) impaired uptake and enhanced release of glutamate, (v) increased electron transport capacity and proton leak, in line with the increased oxidative stress, and (vi) a distinct metabolic profile, with a deficiency in amino acid catabolism and increased sphingolipid metabolism, which have already been linked to MS. INTERPRETATION: Here we describe the metabolic profile of iPSC-derived astrocytes from PwMS and validate this model as a very powerful tool to study disease mechanisms and to perform non-invasive drug targeting assays in vitro. Our findings recapitulate several disease features described in patients and provide new mechanistic insights into the metabolic rewiring of astrocytes in MS, which could be targeted in future therapeutic studies. ANN NEUROL 2022;91:652-669.


Subject(s)
Induced Pluripotent Stem Cells , Multiple Sclerosis , Animals , Astrocytes/metabolism , Glutamic Acid/metabolism , Humans , Induced Pluripotent Stem Cells/metabolism , Mice , Mitochondria/metabolism , Multiple Sclerosis/pathology
3.
Eur J Med Genet ; 63(3): 103737, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31419599

ABSTRACT

Mutations in KDM5C (lysine (K)-specific demethylase 5C) were causally associated with up to 3% of X-linked intellectual disability (ID) in males. By exome and Sanger sequencing, a novel frameshift KDM5C variant, predicted to eliminate the JmjC catalytic domain from the protein, was identified in two monozygotic twins and their older brother, which was inherited from their clinically normal mother, who had completely skewed X-inactivation. DNA methylation (DNAm) data were evaluated using the Illumina 450 K Methylation Beadchip arrays. Comparison of methylation levels between the three patients and male controls identified 399 differentially methylated CpG sites, which were enriched among those CpG sites modulated during brain development. Most of them were hypomethylated (72%), and located mainly in shores, whereas the hypermethylated CpGs were more represented in open sea regions. The DNAm changes did not differ between the monozygotic twins nor between them and their older sibling, all presenting a global hypomethylation, similar to other studies that associated DNA methylation changes to different KDM5C mutations. The 38 differentially methylated regions (DMRs) were enriched for H3K4me3 marks identified in developing brains. The remarkable similarity between the methylation changes in the monozygotic twins and their older brother is indicative that these epigenetic changes were mostly driven by the KDM5C mutation.


Subject(s)
Brain/metabolism , Diseases in Twins/genetics , Histone Demethylases/genetics , Histone Demethylases/metabolism , Intellectual Disability/genetics , Mental Retardation, X-Linked/genetics , Twins, Monozygotic/genetics , Brain/growth & development , Brain/physiopathology , Child , CpG Islands , DNA Methylation , Diseases in Twins/physiopathology , Epigenesis, Genetic , Frameshift Mutation , Genes, X-Linked/genetics , Histones/genetics , Histones/metabolism , Humans , Intellectual Disability/physiopathology , Male , Microarray Analysis , Siblings , Exome Sequencing
5.
Hypertens Res ; 35(7): 733-8, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22357524

ABSTRACT

The factors which contribute to an exaggerated blood pressure response (EBPR) during the exercise treadmill test (ETT) are not wholly understood. The association between the insertion/deletion polymorphisms of the angiotensin-converting enzyme (ACE) and M235T of the angiotensinogen with EBPR during ETT still remains unstudied. To identify and compare the risk factors for hypertension between normotensive subjects with EBPR and those who exhibit a normal curve of blood pressure (BP) during ETT. In a series of EBPR cases from a historical cohort of normotensive individuals, a univariate analysis was performed to estimate the association of the studied factors with BP behavior during ETT. Additionally, logistic multivariate regression was conducted to analyze the joint effects of the variables. P-values above 0.05 were considered statistically significant. From a total of 10,027 analyzed examinations, only 219 met the criteria employed to define EBPR, which resulted in a prevalence of 12.6%. For the systolic component of the BP, hyperreactive subjects displayed a mean age and body mass index (BMI) significantly higher than the others (P=0.002 and <0.001, respectively). No association was observed between the polymorphisms cited above and EBPR. An analysis of the joint effect of variables has indicated that only age (P< 0.001) and BMI (P=0.001) were specifically associated with systolic BP during exercise. Age and BMI were the only factors that independently influenced EBPR during ETT.


Subject(s)
Blood Pressure/physiology , Exercise Test , Hemodynamics/physiology , Adolescent , Adult , Aged , Angiotensinogen/genetics , Blood Pressure/genetics , Cohort Studies , Female , Genetic Association Studies , Hemodynamics/genetics , Humans , Hypertension/genetics , Hypertension/physiopathology , INDEL Mutation , Male , Middle Aged , Peptidyl-Dipeptidase A/genetics , Polymorphism, Genetic , Risk Factors , Young Adult
6.
J Mol Neurosci ; 43(3): 333-6, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20838928

ABSTRACT

Familial idiopathic basal ganglia calcification, also known as "Fahr's disease" (FD), is a neuropsychiatric disorder with autosomal dominant pattern of inheritance and characterized by symmetric basal ganglia calcifications and, occasionally, other brain regions. Currently, there are three loci linked to this devastating disease. The first one (IBGC1) is located in 14q11.2-21.3 and the other two have been identified in 2q37 (IBGC2) and 8p21.1-q11.13 (IBGC3). Further studies identified a heterozygous variation (rs36060072) which consists in the change of the cytosine to guanine located at MGEA6/CTAGE5 gene, present in all of the affected large American family linked to IBGC1. This missense substitution, which induces changes of a proline to alanine at the 521 position (P521A), in a proline-rich and highly conserved protein domain was considered a rare variation, with a minor allele frequency (MAF) of 0.0058 at the US population. Considering that the population frequency of a given variation is an indirect indicative of potential pathogenicity, we screened 200 chromosomes in a random control set of Brazilian samples and in two nuclear families, comparing with our previous analysis in a US population. In addition, we accomplished analyses through bioinformatics programs to predict the pathogenicity of such variation. Our genetic screen found no P521A carriers. Polling these data together with the previous study in the USA, we have now a MAF of 0.0036, showing that this mutation is very rare. On the other hand, the bioinformatics analysis provided conflicting findings. There are currently various candidate genes and loci that could be involved with the underlying molecular basis of FD etiology, and other groups suggested the possible role played by genes in 2q37, related to calcium metabolism, and at chromosome 8 (NRG1 and SNTG1). Additional mutagenesis and in vivo studies are necessary to confirm the pathogenicity for variation in the P521A MGEA6.


Subject(s)
Antigens, Neoplasm/genetics , Genetic Predisposition to Disease , Neoplasm Proteins/genetics , Polymorphism, Single Nucleotide , Amino Acid Sequence , Animals , Basal Ganglia Diseases , Brain Diseases/genetics , Calcinosis/genetics , Computer Simulation , Humans , Male , Middle Aged , Molecular Sequence Data , Neurodegenerative Diseases/genetics , Pedigree , Risk Factors , Sequence Alignment , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...